NeuroSense Therapeutics Reports Positive ALS Treatment Progress and Advances PrimeC to Phase 3 Study

NeuroSense Therapeutics reported 2024 financial results and business updates. The Phase 2b study of PrimeC for ALS showed significant progress, slowing disease progression and improving survival rates. The company plans to advance PrimeC to a Phase 3 study and file for commercialization in Canada, with a potential market opportunity of $100-$150 million. Despite financial challenges, NeuroSense has cash reserves of $3.4 million.